

24. The composition according to Claim 23 wherein the compound is selected from:

- A8
- (a) N-(2-chlorophenyl)-3-oxo-4-aza-4-methyl-5 α -androst-1-ene-17 β -carboxamide,
 - (b) N-(2-fluorophenyl)-3-oxo-4-aza-4-methyl-5 α -androst-1-ene-17 β -carboxamide, and
 - (c) N-(2-trifluoromethyl-phenyl)-3-oxo-4-aza-4-methyl-5 α -androst-1-ene-17 β -carboxamide.

25. The composition according to Claim 24 wherein the compound is N-(2-trifluoromethyl-phenyl)-3-oxo-4-aza-4-methyl-5 α -androst-1-ene-17 β -carboxamide.

REMARKS

The '844 patent issued December 14, 1999, on Application Serial No. 09/029,926 ("the '926 application") filed March 11, 1998, as the national phase application under 35 U.S.C. 371 of PCT Application Serial No. PCT/US96/14564, filed September 11, 1996, based on U.S. Provisional Application Serial No. 60/003,826, filed September 15, 1995.

Claims 1 through 13 were granted in the '844 patent. Claims 2, 3 and 6 to 10 3 have been canceled. Claims 1,4, 5, 9, 10, 13 have been amended, and new Claims 14 through 25 have been added. Currently, Claims 1, 4, 5 and 11 through 25 are pending in the present application.

Claim 1 has been amended to select a single element from the Markush group for R¹ and R². R¹ is now methyl, as specified in originally issued Claim 2. R² has been amended to be hydrogen ("H"), as specified in originally issued Claim 3. In addition, Claim 1 has been amended to add R³ as substituted phenyl, as supported by the specification of the issued patent at column 4, lines 38-51.

Claims 4 and 5, which originally depended on Claim 3, have been amended to depend on amended Claim 1, which incorporates all of the limitations of originally issued Claim 3.

In addition, Claim 4 has been amended to add R³ as substituted phenyl, as supported by the specification of the issued patent at column lines 45 to 60, in particular lines 45-52, 54, 55, and 60.

Reissue Serial No.: To Be Assigned
Reissue of: US 6,001,844
Case No.: 19526PR
Page No.: 13

Claims 5 and 13 have been amended to add species wherein R³ is substituted phenyl, as supported by the specification of the issued patent at column 5, line 64 through column 6, line 15.

New Claims 14 through 16 are directed to compounds wherein R³ is heteroaryl, either unsubstituted or substituted. In these claims, R¹ is supported by originally issued Claim 2 in the '844 patent, and the specification at column 5, line 60; R² is supported by originally issued Claim 3 in the '844 patent. In Claim 14, R³ and R⁴ are supported by originally issued Claim 1 in the '844 patent, and the specification at column 4, lines 38-51, and column 5, lines 11-14. In Claim 15, R³ is supported by originally issued Claim 4 in the '844 patent. Claim 16 finds support in originally issued Claim 5 in the '844 patent.

New Claim 17 finds support throughout the specification, for example at column 5, lines 45 to 60.

New Claim 18 finds support in the specification at column 5, lines 45 to 60, in particular lines 45-52, 54, 55, and 60.

New Claim 19 finds support in the specification at column 5, line 64 through column 6, line 15.

New Claim 20 finds support in column 4, lines 38-51, in particular, lines 38-40 and 42.

New Claim 21 finds support in the specification as Examples 3, 4, and 6, appearing in column 15 as the second, third, and fifth entry in the table, as well as in column 6, lines 1, 2, 5-8.

New Claim 22 finds support in the specification as Example 4, appearing in column 15 as the third entry in the table, and in column 6, lines 7-8.

New Claim 23 to 26 find support in originally issued Claim 11 of the '844 patent. In addition, Claim 23 finds support in the specification at column 5, line 64 through column 6, line 15. Claim 24 finds support in the specification as Examples 3, 4, and 6, appearing in column 15 as the second, third, and fifth entry in the table, as well as in column 6, lines 1, 2, 5-8. Claim 24 finds additional support in the specification as Example 4, appearing in column 15 as the third entry in the table, and in column 6, lines 7-8.

The specification has been amended to correct minor typographical errors. In particular, in the paragraph beginning at column 5, line 15, "pennissible" has been corrected to read --permissible--; in the paragraph beginning at column 8, line 42, both "mgas/g" and "msg/kg" have been corrected to read --mg/kg--; in the paragraph beginning at column 16, line 34, "jodomethane" has been corrected to read --iodomethane--; and in the paragraph beginning at column 20, line 60, "photographss" has been corrected to read --photographs--.

Reissue Serial No.: To Be Assigned
Reissue of: US 6,001,844
Case No.: 19526PR
Page No.: 14

The amendments above to the specification and claims do not add new matter to the present reissue application.

Applicants respectfully submit that the submitted claims are proper, and their allowance in this reissue application is respectfully requested.

Respectfully submitted,

By


Catherine D. Fitch, Reg. No. 36,502
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065
Tel.: (732)594-4283

December 14, 2001